ATTD 2026
Advanced Technologies & Treatments for Diabetes
A topic-first companion to the ATTD program. Browse the four-day agenda by theme — CGM, AI & digital health, closed-loop, T1D, T2D, pregnancy, pediatrics — and dive into the transcripts and slide notes attached to each session.
Plenary & Keynote
7 sessions · 35 notesOpening, scientific plenaries, ATTD Yearbook, closing remarks — the through-line of the meeting.
Welcome Reception
Hot from the Oven
Late-breaking and just-published research highlights.
配備自動化胰島素給藥系統之新型感測器的真實世界效能分析 (Performance of a newly introduced sensor with AID system: A real-world analysis)#day:2026-03-12#room:Auditorium#track:plenary
結合 CGM 的胰島素劑量指引系統之臨床評估:Type 1 與 Type 2 糖尿病患者之應用#day:2026-03-12#room:Auditorium#track:plenary
Jeremy Pettus|THE PROGRESS STUDY: PHASE 1/2 CLINICAL TRIAL OF KRIYA-839, A NOVEL AAV GENE THERAPY FOR ADULTS WITH TYPE 1 DIABETES#day:2026-03-12#room:Auditorium#track:plenary
Viral N. Shah|PERFORMANCE OF A NEWLY INTRODUCED SENSOR WITH AID SYSTEM: A REAL-WORLD ANALYSIS#day:2026-03-12#room:Auditorium#track:plenary
Emma G. Wilmot|FREEDM2 RCT: NEW INSIGHTS INTO CGM WITH BASAL INSULIN IN T2DM#day:2026-03-12#room:Auditorium#track:plenary
Andrej Janež|EVALUATION OF CGM-BASED INSULIN DOSE GUIDANCE SYSTEM IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES: SINGLE ARM FEASIBILITY STUDY#day:2026-03-12#room:Auditorium#track:plenary
Stefano Del Prato|EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES: RESULTS FROM SURPASS-EARLY STUDY AFTER 2 YEARS OF TREATMENT#day:2026-03-12#room:Auditorium#track:plenary
Scientific Plenary: What Else Is New?
國際共識:早期第一型糖尿病的篩檢與監測——邁向歐洲實施的藍圖#day:2026-03-13#room:Hall 115#track:plenary
第 1 型糖尿病的 GLP/GIP 輔助治療:共識報告與安全使用指南#day:2026-03-13#room:Hall 115#track:plenary
ADJUNCTIVE TREATMENT WITH GLP/GIPS FOR PATIENTS WITH TYPE 1 DIABETES: CONSENSUS REPORT AND GUIDELINES FOR SAFER USE#day:2026-03-13#room:Hall 115#track:plenary
AN INTERNATIONAL CONSENSUS ON SCREENING AND MONITORING EARLY-STAGE TYPE 1 DIABETES: A ROADMAP TO EUROPEAN IMPLEMENTATION – Online First Release#day:2026-03-13#room:Hall 115#track:plenary
Scientific Plenary: ATTD Yearbook Session
糖尿病治療中運動與營養的最新進展#day:2026-03-13#room:Auditorium#track:plenary
OBESITY AND DIABETES#day:2026-03-13#room:Auditorium#track:plenary
THE REAL REAL WORLD - 克服糖尿病科技在現實世界中的實際障礙與不平等#day:2026-03-13#room:Auditorium#track:plenary
CONTINUOUS AND INTERMITTENT GLUCOSE MONITORING#day:2026-03-13#room:Auditorium#track:plenary
科技與妊娠:糖尿病科技與治療的核心進展#day:2026-03-13#room:Auditorium#track:plenary
NEW INSULINS, BIOSIMILARS AND INSULIN THERAPY#day:2026-03-13#room:Auditorium#track:plenary
PRIMARY CARE AND DIABETES TECHNOLOGIES AND TREATMENTS#day:2026-03-13#room:Auditorium#track:plenary
VIRTUAL CLINICS FOR DIABETES CARE#day:2026-03-13#room:Auditorium#track:plenary
USE OF TECHNOLOGIES AT THE ADVANCED AGE#day:2026-03-13#room:Auditorium#track:plenary
USING DIGITAL HEALTH TECHNOLOGY TO PREVENT AND TREAT DIABETES#day:2026-03-13#room:Auditorium#track:plenary
EMERGING TRENDS IN MASLD AND MASH#day:2026-03-13#room:Auditorium#track:plenary
IMMUNE INTERVENTION AND BETA CELL REPLACEMENT THERAPIES IN TYPE 1 DIABETES#day:2026-03-13#room:Auditorium#track:plenary
CLOSED-LOOP, DECISION SUPPORT, AND ARTIFICIAL INTELLIGENCE#day:2026-03-13#room:Auditorium#track:plenary
DIABETES TECHNOLOGY AND THERAPY IN THE PEDIATRIC AGE GROUP#day:2026-03-13#room:Auditorium#track:plenary
第五章:閉環系統、決策支援與人工智慧#day:2026-03-13#room:Auditorium#track:plenary
INSULIN DELIVERY HARDWARE: PUMPS AND PENS#day:2026-03-13#room:Auditorium#track:plenary
TECHNOLOGY AND PREGNANCY#day:2026-03-13#room:Auditorium#track:plenary- Jennifer Sherr|CONTINUOUS AND INTERMITTENT GLUCOSE MONITORING#day:2026-03-13#room:Auditorium#track:plenary
Michael C. Riddell|ADVANCES IN EXERCISE AND NUTRITION AS THERAPY IN DIABETES#day:2026-03-13#room:Auditorium#track:plenary
Viral N. Shah|OBESITY AND DIABETES#day:2026-03-13#room:Auditorium#track:plenary- Satish K. Garg|VIRTUAL CLINICS FOR DIABETES CARE#day:2026-03-13#room:Auditorium#track:plenary
IMPACT OF DIABETES TECHNOLOGIES ON PSYCHOSOCIAL OUTCOMES#day:2026-03-13#room:Auditorium#track:plenary
Closing Remarks
Farewell Refreshments
CGM & Glucose Monitoring
8 sessions · 28 notesContinuous glucose monitoring from real-life use, beyond traditional indications, to data interoperability and gold-standard debates.
Parallel Scientific 04: Real-Life Use of Continuous Glucose Monitoring (CGM)
Parallel Scientific 12: From Prediction to Diabetes Complications
Parallel Scientific 13: Debate — HbA1c and Not CGM Should Be the Gold Standard to Evaluate Glucose Control
REBUTTAL BY SPEAKER PRESENTING CON#day:2026-03-13#room:Hall 211#track:cgm
REBUTTAL BY SPEAKER PRESENTING PRO#day:2026-03-13#room:Hall 211#track:cgm
第十九屆先進糖尿病科技與治療國際研討會 (ATTD) 辯論:糖化血色素 (HbA1c) 是否應維持作為評估血糖控制的主要指標?#day:2026-03-13#room:Hall 211#track:cgm
糖化血色素(HbA1c)與連續血糖監測(CGM)的黃金標準之爭#day:2026-03-13#room:Hall 211#track:cgm
跨越橋樑:從 A1C 時代邁向 CGM 測量與管理的全新紀元 (Crossing the Bridge from A1C to CGM Measurement & Management)#day:2026-03-13#room:Hall 211#track:cgm
Elizabeth Selvin|PRO#day:2026-03-13#room:Hall 211#track:cgm
Richard M. Bergenstal|CON#day:2026-03-13#room:Hall 211#track:cgm
Elizabeth Selvin|REBUTTAL BY SPEAKER PRESENTING PRO#day:2026-03-13#room:Hall 211#track:cgm
Richard M. Bergenstal|REBUTTAL BY SPEAKER PRESENTING CON#day:2026-03-13#room:Hall 211#track:cgm- Q&A|Q&A#day:2026-03-13#room:Hall 211#track:cgm
Parallel Scientific 23: Updates on Hypo- and Hyperglycemia
Stephanie Amiel|CLEAR AND HARPdoc - NEW LEARNING FROM STUDIES IN IMPAIRED HYPOGLYCAEMIA AWARENESS#day:2026-03-14#room:Hall 117#track:cgm- Session-level|Parallel Scientific 23: Updates on Hypo- and Hyperglycemia#day:2026-03-14#room:Hall 117#track:cgm
Q&A|Q&A (Updates on hypo-/hyperglycemia)#day:2026-03-14#room:Hall 117#track:cgm
David C. Klonoff|UPDATE ON THE CLINICAL USE OF GLYCEMIC RISK INDEX (GRI)#day:2026-03-14#room:Hall 117#track:cgm
Yu Kuei|HYPOGLYCEMIA RISK IN INSULIN-TREATED DIABETES WITH CGM USE: WHAT REMAINS THE SAME AND WHAT MAY BE DIFFERENT?#day:2026-03-14#room:Hall 117#track:cgm
Ivana Rabbone|LONG-TERM IMPACT OF EARLY ADVANCED TECHNOLOGY ADOPTION (CGM/AID) ON HYPOGLYCEMIA AWARENESS AND FEAR IN CHILDREN AND FAMILIES#day:2026-03-14#room:Hall 117#track:cgm- Parallel Scientific 23: Updates on Hypo- and Hyperglycemia#day:2026-03-14#room:Hall 117#track:cgm
Oral Presentations 07: Use of CGM in Practice
Parallel Scientific 28: Continuous Glucose Monitoring (CGM) Outside the Traditional Areas
Q&A|Q&A (CGM outside traditional areas)#day:2026-03-14#room:Hall 112#track:cgm
Pratik Choudhary|CGM USE IN CLINICAL TRIALS#day:2026-03-14#room:Hall 112#track:cgm
Lutz W. Heinemann|NON-INVASIVE GLUCOSE MONITORING#day:2026-03-14#room:Hall 112#track:cgm
Robert Andrews|CGM IN NON-DIABETIC HYPOGLYCAEMIA (INSULINOMA, POST-BARIATRIC / REACTIVE)#day:2026-03-14#room:Hall 112#track:cgm
Nicola Guess|CGM AS A GUIDE TO LIFESTYLE AND WEIGHT MANAGEMENT#day:2026-03-14#room:Hall 112#track:cgm
Oral Presentations 09: Use of CGM and Other Technologies in Diabetes
Oral Presentations 13: Updates on Glucose Monitoring
Automated Insulin Delivery
5 sessions · 19 notesClosed-loop systems — where they are now, adjunct therapies, updates on AID, and bridging academia with industry.
Parallel Scientific 07: Closed-Loop Systems — Where Are We Now?
Parallel Scientific 17: Adjunct Therapies with Automated Insulin Delivery
Janet K. Snell-Bergeon|ADJUST T1D STUDY - CARDIOVASCULAR OUTCOMES#day:2026-03-13#room:Hall 112#track:aid
Francisco J. Pasquel - 第一型糖尿病使用 GLP-1 的真實世界數據#day:2026-03-13#room:Hall 112#track:aid
SGLT-2 抑制劑與連續酮體監測 (CKM) 的臨床目標#day:2026-03-13#room:Hall 112#track:aid
講題:自動胰島素給藥系統(AID)與 SGLT2 抑制劑的合併使用#day:2026-03-13#room:Hall 112#track:aid
Viral N. Shah|ADJUST T1D STUDY – DESIGN AND GLYCEMIC OUTCOME#day:2026-03-13#room:Hall 112#track:aid
Ahmad Haidar|CONCURRENT USE OF AID WITH SGLT-2#day:2026-03-13#room:Hall 112#track:aid
Francisco J. Pasquel|REAL-LIFE DATA ON GLP USE IN TYPE 1 DIABETES#day:2026-03-13#room:Hall 112#track:aid- Q&A|Q&A#day:2026-03-13#room:Hall 112#track:aid
Parallel Scientific 25: Updates on Automated Insulin Delivery (AID)
綜合問答與討論 (Q&A)#day:2026-03-14#room:Hall 211#track:aid
Gregory P. Forlenza|IS ULTRA-FAST ACTING INSULIN IMPROVING AID – THE EVIDENCE IS MIXED, BUT THERE IS A CATCH#day:2026-03-14#room:Hall 211#track:aid- Session-level|Parallel Scientific 25: Updates on Automated Insulin Delivery (AID)#day:2026-03-14#room:Hall 211#track:aid
Jennifer Sherr|OPTIMIZING AID SYSTEMS: STRATEGIES FOR ENHANCED GLYCEMIC CONTROL#day:2026-03-14#room:Hall 211#track:aid
Revital Nimri|TWENTY-FIVE-HOUR FASTING WITH HYBRID CLOSED-LOOP#day:2026-03-14#room:Hall 211#track:aid
Mohammed Al-Sofiani|FASTING DURING RAMADAN WITH AID SYSTEMS#day:2026-03-14#room:Hall 211#track:aid- Parallel Scientific 25: Updates on Automated Insulin Delivery (AID)#day:2026-03-14#room:Hall 211#track:aid
Oral Presentations 05: Closed-Loop Systems (1)
EARLY INTENSIVE INSULIN THERAPY WITH AN AHCL SYSTEM AT THE ONSET OF ASYMPTOMATIC TYPE 1 DIABETES MELLITUS: CLINICAL EXPERIENCE IN THREE PEDIATRIC PATIENTS.#day:2026-03-14#room:Hall 115#track:aid
Omnipod 5 自動胰島素給藥 (AID) 系統在第2型糖尿病患者的最佳預後設定#day:2026-03-14#room:Hall 115#track:aid
連續血糖監測衍生指標與 HbA1c 之間的關係:MiniMed 780G 系統關鍵試驗探討#day:2026-03-14#room:Hall 115#track:aid
針對第一型糖尿病的多變數全自動胰島素傳輸系統 (Multivariable Fully-Automated Insulin Delivery for T1D)#day:2026-03-14#room:Hall 115#track:aid
Oral Presentations 10: Closed-Loop Systems (2)
AI, Big Data & Digital Health
5 sessions · 27 notesAI in diabetes care — from foundational decision support to agentic CDSS workflows. ATTD AI School, plenaries, oral sessions on big data.
Scientific Plenary: Transforming Diabetes Management with Artificial Intelligence (AI)
結合數位分身與大型語言模型:第一型糖尿病的進階個人化胰島素治療#day:2026-03-12#room:Auditorium#track:ai
COMBINING DIGITAL TWINS AND LLMS FOR ADVANCED PERSONALIZED INSULIN THERAPY IN TYPE 1 DIABETES#day:2026-03-12#room:Auditorium#track:ai
Heman Shakeri|A WEEK OF AUTOMATED INSULIN DELIVERY USED TO TITRATE BASAL INSULIN IN TYPE 2 DIABETES#day:2026-03-12#room:Auditorium#track:ai
Marc D. Breton|FULLY AUTOMATED CLOSED-LOOP BASED ON ARTIFICIAL INTELLIGENCE#day:2026-03-12#room:Auditorium#track:ai
Oral Presentations 01: Big Data and AI-Based Decision Support Systems
Generating Longitudinal Synthetic Data in Type 2 Diabetes Using Dynamic Bayesian Networks: A Case Study#clientRef:3a10b532e10fcdf8#track:ai#day:D2
AI-Enhanced Prediction of Extreme Insulin Resistance: A Machine Learning Breakthrough for Precision Diabetes Care#clientRef:ad467f500d5cc1b3#track:ai#day:D2
Building Data-Based Digital Twins in Diabetes with Deep Generative Models: Progress and Challenges#clientRef:799ce669c4958fdc#track:ai#day:D2
預測低血糖事件的混合深度學習與機制模型#day:2026-03-12#room:Hall 212#track:ai
晝夜血糖智能:AI 發現的時序生物標記能在臨床表現前 3-4 年預測糖尿病併發症#day:2026-03-12#room:Hall 212#track:ai
利用動態貝氏網路生成第二型糖尿病縱向合成數據:以 LEADER 試驗數據集為例的案例研究#day:2026-03-12#room:Hall 212#track:ai
EXPERIENCED DIABETES PROVIDERS’ EVALUATION OF A DIGITAL-TWIN RECOMMENDER DECISION SUPPORT SYSTEM FOR MULTIPLE DAILY INJECTION (MDI) THERAPY IN TYPE 1 DIABETES (T1D)#day:2026-03-12#room:Hall 212#track:ai
Parallel Scientific 11: Revolutionizing Diabetes Care — Artificial Intelligence, Machine Learning and Continuous Glucose Monitoring in Practice
ADVANCED CGM/AI-BASED ALGORITHMS FOR DIABETES#day:2026-03-13#room:Hall 117#track:ai
OPTIMIZING GLYCEMIC CONTROL WITH ARTIFICIAL INTELLIGENCE & MACHINE LEARNING: LESSONS LEARNED AND NEXT STEPS#day:2026-03-13#room:Hall 117#track:ai
轉變糖尿病管理的未來:人工智慧與連續血糖監測的結合#day:2026-03-13#room:Hall 117#track:ai
Joseph Vehi|OPTIMIZING GLYCEMIC CONTROL WITH ARTIFICIAL INTELLIGENCE & MACHINE LEARNING: LESSONS LEARNED AND NEXT STEPS#day:2026-03-13#room:Hall 117#track:ai
Andrea Facchinetti|ADVANCED CGM/AI-BASED ALGORITHMS FOR DIABETES#day:2026-03-13#room:Hall 117#track:ai
Halis K. Akturk|THE ROLE OF CGM IN EARLY DETECTION OF IMMUNE CHECKPOINT INHIBITOR (CANCER IMMUNOTHERAPY) INDUCED TYPE 1 DIABETES#day:2026-03-13#room:Hall 117#track:ai
Parallel Scientific 14: Data Interoperability
THE NEED FOR INTEROPERABILITY#day:2026-03-13#room:Hall 116#track:ai
講者一 (Johan) 結語:資料所有權、法規與資安挑戰#day:2026-03-13#room:Hall 116#track:ai
Johan Jendle|THE NEED FOR INTEROPERABILITY#day:2026-03-13#room:Hall 116#track:ai
Iain Cranston|DATA STANDARDS AND DATA OWNERSHIP FOR DEVICE INTEROPERABILITY – THE NHSE / PRSB EXPERIENCE & DEBATE#day:2026-03-13#room:Hall 116#track:ai
Peter Adolfsson|HOW ARE DATA BEING INTEGRATED INTO EHRS?#day:2026-03-13#room:Hall 116#track:ai
Parallel Scientific 35: ATTD AI School for Clinicians — From GenAI Foundations to Agentic CDSS Workflows: Safe, Practical Use in Diabetes Care
Amit K. Dey, Lucia Feito Allonca, Revital Nimri, Peter Schwarz|PANEL DISCUSSION - Q &A;#day:2026-03-14#room:Hall 114#track:ai
Lucia Feito Allonca|ETHICS, EU AI ACT & GDPR ESSENTIALS FOR CLINICIANS#day:2026-03-14#room:Hall 114#track:ai
Revital Nimri|AGENTIC AI & CDSS WORKFLOWS IN DIABETES CARE#day:2026-03-14#room:Hall 114#track:ai
Amit K. Dey|FOUNDATIONS OF AI & GEN-AI FOR CLINICIANS#day:2026-03-14#room:Hall 114#track:ai
Amit K. Dey, Peter Schwarz|WELCOME & FRAMING#day:2026-03-14#room:Hall 114#track:ai
Type 1 Diabetes
11 sessions · 39 notesScreening, prevention, cell replacement therapy, cardiovascular risk, refining care — the full T1D arc across all four days.
EDENT1FI Symposium
EDENT1FI consortium symposium on early detection of type 1 diabetes.
Breakthrough T1D — ATTD Interventional Type 1 Diabetes Course
Parallel Scientific 01: Screening and Treatment Options for Delaying Onset of Type 1 Diabetes
臨床推廣與問答環節:將第一型糖尿病篩檢落實於常規照護 (Haller 教授總結與 Q&A)#day:2026-03-12#room:Hall 117#track:t1d
篩檢第一型糖尿病的美國計畫:從研究邁向標準照護 (SCREENING PROGRAMS FOR TYPE 1 DIABETES IN THE US - FROM RESEARCH TO STANDARD OF CARE)#day:2026-03-12#room:Hall 117#track:t1d
Q &A;#day:2026-03-12#room:Hall 117#track:t1d
IS IT TIME TO RE-EVALUATE OUR RECOMMENDATIONS FOR SCREENING THE GENERAL POPULATION FOR RISK FOR TYPE 1 DIABETES?#day:2026-03-12#room:Hall 117#track:t1d
COST EFFECTIVENESS OF SCREENING AND IMMUNE INTERVENTIONS IN TYPE 1#day:2026-03-12#room:Hall 117#track:t1d
Parallel Scientific 08: Global Stages of Screening of Type 1 Diabetes
Oral Presentations 04: Screening, Prevention and Cure of Diabetes
CURRENT GMI CAN OVER DIAGNOSE PREDIABETES WITH UPDATED GMI AND TITR MITIGATTING THIS RISK#day:2026-03-13#room:Hall 212#track:t1d
DETECTION OF GENETIC SUSCEPTIBILITY TO TYPE 2 DIABETES MELLITUS VIA MACHINE LEARNING APPROACH: MIR-122 AS A POTENTIAL PREDICTOR#day:2026-03-13#room:Hall 212#track:t1d
前導演講結尾:uGMI 與嚴格目標範圍內時間的臨床應用#day:2026-03-13#room:Hall 212#track:t1d
從糖尿病前期或第二型糖尿病重新分類為第一型糖尿病:來自真實世界的證據#day:2026-03-13#room:Hall 212#track:t1d
第 19 屆 ATTD 國際研討會:口頭發表第四場次 (Oral Presentation Session 04)#day:2026-03-13#room:Hall 212#track:t1d
Parallel Scientific 16: Breakthrough T1D (JDRF) Session — Cell Replacement Therapy: Functional Cure for Type 1 Diabetes — How Far Are We?
**優化免疫調節以改善第1型糖尿病患者β細胞替代療法之成效**#day:2026-03-13#room:Hall 117#track:t1d
利用奈米粒子平台確保微創幹細胞衍生胰島移植的安全性與成功率#day:2026-03-13#room:Hall 117#track:t1d
幹細胞衍生 β 細胞於細胞治療之應用:進展、障礙與未來方向#day:2026-03-13#room:Hall 117#track:t1d
Per-Ola Carlsson|HYPOIMMUNE PANCREATIC ISLET TRANSPLANTATION IN TYPE 1 DIABETES#day:2026-03-13#room:Hall 117#track:t1d
Holger Russ|STEM CELL DERIVED BETA CELLS FOR CELL THERAPY: PROGRESS, HURDLES AND FUTURE DIRECTIONS#day:2026-03-13#room:Hall 117#track:t1d
Katy Digovich|MINUTIA: LEVERAGING OUR NANOPARTICLE PLATFORM FOR SAFETY AND SUCCESS WITH OUR MINIMALLY INVASIVE SC-ISLET TRANSPLANT#day:2026-03-13#room:Hall 117#track:t1d
Piotr Witkowski|OPTIMIZING IMMUNOMODULATION TO IMPROVE OUTCOMES OF BETA CELL REPLACEMENT THERAPY IN PATIENTS WITH T1DM#day:2026-03-13#room:Hall 117#track:t1d- Q&A|Q&A#day:2026-03-13#room:Hall 117#track:t1d
Parallel Scientific 24: Cardiovascular Disease in Type 1 Diabetes
Q&A|Q&A (Cardiovascular disease in T1D)#day:2026-03-14#room:Hall 112#track:t1d
Irl B. Hirsch|UNDERSTANDING THE ETIOLOGY AND BEST TREATMENT STRATEGIES FOR OBESITY IN TYPE 1 DIABETES#day:2026-03-14#room:Hall 112#track:t1d
Kirsten Nørgaard|PHYSICAL ACTIVITY FOR CARDIOMETABOLIC RISK REDUCTION IN TYPE 1 DIABETES#day:2026-03-14#room:Hall 112#track:t1d
Robert H. Eckel|CORONARY HEART DISEASE IN T1D, IS IT DIFFERENT THAN IN T2D?#day:2026-03-14#room:Hall 112#track:t1d
Parallel Scientific 26: Refining Care of Type 1 Diabetes
Katharine D. Barnard-Kelly|IMPROVING GLYCEMIC CONTROL AND REDUCING DIABETES DISTRESS: A 2-WAY STREET#day:2026-03-14#room:Hall 114#track:t1d
Lori M. Laffel|EXECUTIVE FUNCTION AND USE OF DIABETES TECHNOLOGIES#day:2026-03-14#room:Hall 114#track:t1d
Roy W. Beck|INHALED INSULIN USE IN PEDIATRICS – INHALE 1 STUDY#day:2026-03-14#room:Hall 114#track:t1d
David M. Maahs|TARGETING LOWER GLUCOSE LEVELS IN CHILDREN WITH TYPE 1 DIABETES#day:2026-03-14#room:Hall 114#track:t1d
Parallel Scientific 27: Navigating Early Type 1 Diabetes — From Screening to Management
Riccardo Bonfanti|THE ROLE OF TECHNOLOGY IN MONITORING AND MANAGING PRESYMPTOMATIC (STAGE 1 & 2) TYPE 1 DIABETES IN CHILDREN FOLLOWING SCREENING#day:2026-03-14#room:Hall 117#track:t1d
Korey Hood|EXPERIENCE OF BEING ANTI-BODY POSITIVE AND CHOICES AVAILABLE#day:2026-03-14#room:Hall 117#track:t1d
Katharine D. Barnard-Kelly|IMPACT OF SCREENING AND UNDERSTANDING THE RISK#day:2026-03-14#room:Hall 117#track:t1d
Parallel Scientific 29: Breakthrough T1D (JDRF) Session — Bridging the Gap Between Academia and Industry in Diabetes Technology
Timothy Dunn|SHARING INSIGHTS FROM THE INDUSTRY PERSPECTIVE#day:2026-03-14#room:Hall 211#track:t1d
Jared Tangney|THE BIOLINQ JOURNEY: FROM UNIVERSITY LAB TO FDA CLEARANCE#day:2026-03-14#room:Hall 211#track:t1d
Koji Sode|BRIDGING THE GAP BETWEEN ACADEMIA AND INDUSTRY IN DIABETES TECHNOLOGY: AN ACADEMIC PERSPECTIVE#day:2026-03-14#room:Hall 211#track:t1d
Q&A|Q&A (Bridging academia and industry in diabetes technology)#day:2026-03-14#room:Hall 211#track:t1d
Scientific Plenary: Advancements in Type 1 Diabetes — From Pathogenesis to Therapy
Chantal Mathieu|C-PEPTIDE: A MARKER FOR FUNCTIONAL BETA CELL MASS?#day:2026-03-14#room:Hall 113#track:t1d
Jason Gaglia|DENDRITIC CELLS FOR TREATMENT OF TYPE 1 DIABETES#day:2026-03-14#room:Hall 113#track:t1d
Teresa Rodriguez-Calvo|ROLE OF VIRUSES IN PATHOGENESIS OF TYPE 1 DIABETES#day:2026-03-14#room:Hall 113#track:t1d
Type 2 Diabetes
3 sessions · 3 notesTechnology adoption in T2D, basal insulin strategies, and outcomes for people with type 2 diabetes.
Parallel Scientific 09: The Use of Technology in Treating Type 2 Diabetes
Parallel Scientific 19: Betting on Basal Insulin — Improving the Odds for People with Type 2 Diabetes
Not included in the main event CME/CPD credit.
Oral Presentations 06: Medications for Treatment of Diabetes
Pregnancy & Special Populations
3 sessions · 8 notesPregnancy, older adults, female health, and other populations whose diabetes care diverges from the default playbook.
Parallel Scientific 02: Use of Technology in Older Adults with Diabetes
Parallel Scientific 05: Updates on Diabetes Management and Females' Health
Parallel Scientific 18: Using Technology in Pregnancy
妊娠期早發型第二型糖尿病的懷孕結局 (Pregnancy Outcomes in Early-Onset Type 2 Diabetes)#day:2026-03-13#room:Hall 211#track:special
Helen Murphy|PREGNANCY OUTCOMES IN EARLY-ONSET TYPE 2 DIABETES#day:2026-03-13#room:Hall 211#track:special
Janni E. Larsson|DIABETIC RETINOPATHY IN RELATION TO PREGNANCY#day:2026-03-13#room:Hall 211#track:special
Eleanor Scott|EXPANDING CGM USE IN GDM PREGNANCY#day:2026-03-13#room:Hall 211#track:special
Q&A|Q&A#day:2026-03-13#room:Hall 211#track:special
Pediatric Diabetes
1 session · 3 notesISPAD session, pediatric updates on technology, guidelines, and global outreach.
Parallel Scientific 34: ISPAD Session — Pediatric Diabetes: Updates on Technology, Guidelines, and Global Outreach
Nicole Glaser|ISPAD DKA GUIDELINES - WHAT IS NEW?#day:2026-03-14#room:Hall 211#track:pediatric
Martin Tauschmann|CONTINUOUS GLUCOSE MONITORING (CGM) ACCURACY - BALANCING ACCESS, COST AND SAFETY#day:2026-03-14#room:Hall 211#track:pediatric
Graham D. Ogle|EQUITY IN ACTION: LESSONS FROM THE GLOBAL SOUTH IN DELIVERING DIABETES CARE FOR CHILDREN#day:2026-03-14#room:Hall 211#track:pediatric
Insulin Therapy & Smart Pens
2 sessions · 14 notesNew insulins, insulin delivery systems, and the rise of smart pens — opportunities and hurdles.
Oral Presentations 02: New Insulins and Insulin Delivery Systems
Patients Knowledge and Barriers to Ketone Self-Monitoring: Results from a Prospective Survey#clientRef:053d616f8a687536#track:insulin#day:D2
連續腹腔內胰島素輸注:國際立場聲明 (Continuous Intraperitoneal Insulin Infusion: An International Position Statement)#day:2026-03-12#room:Hall 212#track:insulin
連續腹腔內胰島素輸注:國際共識聲明 (Continuous Intraperitoneal Insulin Infusion - An International Consensus Statement)#day:2026-03-12#room:Hall 212#track:insulin
第一型糖尿病患者對酮體自我監測的知識與障礙——法國 SFDT1 世代前瞻性調查結果#day:2026-03-12#room:Hall 212#track:insulin
比較 Tandem Control-IQ 與 MiniMed 780G 的相對療效:一項為期 6 個月的前瞻性研究#day:2026-03-12#room:Hall 212#track:insulin
使用 CGM 指標指導第 2 型糖尿病患者每週一次基礎胰島素之劑量滴定#day:2026-03-12#room:Hall 212#track:insulin
STEADY-STATE PHARMACOKINETICS AND GLUCODYNAMICS OF ONCE-WEEKLY INSULIN EFSITORA ALFA (EFSITORA) IN INDIVIDUALS WITH TYPE 2 DIABETES (T2D)#day:2026-03-12#room:Hall 212#track:insulin
EFFICACY AND SAFETY OF ONCE-WEEKLY BASAL INSULIN EFSITORA COMPARED TO INSULIN DEGLUDEC IN INSULIN NAÏVE EAST ASIAN ADULTS WITH TYPE 2 DIABETES#day:2026-03-12#room:Hall 212#track:insulin
DURATION OF HYPOGLYCAEMIA WITH ONCE-WEEKLY INSULIN EFSITORA ALFA VERSUS ONCE-DAILY BASAL INSULINS IN ADULTS WITH TYPE 2 DIABETES: EXPLORATORY ANALYSIS OF QWINT 2-4#day:2026-03-12#room:Hall 212#track:insulin
Parallel Scientific 33: Opportunities and Hurdles for Smart Pens
Q&A|Q&A (Opportunities and hurdles for smart pens)#day:2026-03-14#room:Hall 112#track:insulin
Peter Adolfsson|USAGE OF SMART PENS IN PEDIATRIC POPULATION#day:2026-03-14#room:Hall 112#track:insulin
Lutz W. Heinemann|NEXT GENERATION OF SMART PENS#day:2026-03-14#room:Hall 112#track:insulin
Johan Jendle|CLINICAL EVIDENCE FOR SMART PENS#day:2026-03-14#room:Hall 112#track:insulin
Dominic Ehrmann|HCPS AND PATIENTS' VIEW ON SMART PENS: RESULTS OF THE DT-REPORT 2025#day:2026-03-14#room:Hall 112#track:insulin
Nutrition, Exercise & Obesity
6 sessions · 19 notesExercise physiology and metabolism, nutrition and food technologies, treating obesity in T1D and beyond.
Parallel Scientific 03: Exercise Physiology and Metabolism in Diabetes — From Theory to Clinical Application
Parallel Scientific 06: The Leona M. and Harry B. Helmsley Charitable Trust Session — Pushing the Field of Exercise Forward for People Living with Type 1 Diabetes
運用乳清蛋白降低第一型糖尿病患者運動期間的低血糖風險 (Use of Whey Protein to Reduce Risk of Hypoglycemia During Exercise for People with T1D)#day:2026-03-12#room:Hall 117#track:lifestyle
迎向運動新進展:血糖管理的胰島素與衛教策略 (Moving Forward with Exercise - Insulin and Education Strategies for Glycemic Management)#day:2026-03-12#room:Hall 117#track:lifestyle- 專家問答交流 (Q&A Session)#day:2026-03-12#room:Hall 117#track:lifestyle
Deniz Dalton - HELMSLEY 基金會的資助領域與第一型糖尿病及運動倡議 (T1-DEXI)#day:2026-03-12#room:Hall 117#track:lifestyle
Parallel Scientific 10: Nutrition and Food Technologies
Oral Presentations 03: Physical Activities and Diabetes
CAPTAIN MOBI: A REAL-WORLD DATA STUDY DESIGN FOR EVALUATING AUTOMATED INSULIN DELIVERY IN COMPETITIVE YOUTH ATHLETES WITH TYPE 1 DIABETES#day:2026-03-13#room:Hall 115#track:lifestyle
Denise Montt-Blanchard - DIACTIV - THERAPEUTIC INTERFACE BRIDGING EXERCISE, BEHAVIORAL, AND TECHNOLOGICAL GAPS IN ADOLESCENTS WITH TYPE 1 DIABETES#day:2026-03-13#room:Hall 115#track:lifestyle
使用 AID 的第一型糖尿病患者在體能活動期間低血糖發作的預測因素:來自 RAPPID 多中心研究的發現#day:2026-03-13#room:Hall 115#track:lifestyle
針對第一型糖尿病患者使用 AID 系統於運動期間之 CGM 與臨床症狀不匹配的低血糖偵測:來自 RAPPID 多中心研究的發現#day:2026-03-13#room:Hall 115#track:lifestyle
Parallel Scientific 22: Managing Overweight & Obesity in Type 1 Diabetes
引言與講者介紹#day:2026-03-13#room:Hall 212#track:lifestyle
第一型糖尿病的肥胖問題與心血管代謝風險 (講者:Lea)#day:2026-03-13#room:Hall 212#track:lifestyle
Adrian Brown|ESSENTIAL NUTRITION SUPPORT FOR GLP-1/GIP THERAPY SUCCESS#day:2026-03-13#room:Hall 212#track:lifestyle- Q&A|Q&A#day:2026-03-13#room:Hall 212#track:lifestyle
THE ROLE OF PSYCHOLOGICAL INTERVENTIONS IN PROMOTING SUSTAINABLE WEIGHT LOSS#day:2026-03-13#room:Hall 212#track:lifestyle
Oral Presentations 11: Treating Obesity
Equity, Education & Care Delivery
9 sessions · 28 notesEquity and disparities, nursing, healthcare-provider challenges, ATTD x UNLOK x IDF education, and population-level innovation.
#dedoc° Symposium
#dedoc° voices — patient advocacy and lived-experience perspectives in diabetes tech.
Parallel Scientific 15: IDF Europe Symposium — From Diabetes Detection to Cure: Turning Vision into Reality
Lunch boxes are offered.
IDF Europe Symposium: International Consensus on Early-Stage Type 1 Diabetes Detection and Monitoring#day:2026-03-13#room:Hall 113#track:care
IDF Europe Symposium: #LanguageMatters in Population Screening for Stage 1 T1D#day:2026-03-13#room:Hall 113#track:care
IDF Europe Symposium: Cardiovascular Disease Prevention for People with Dysglycemia and Diabetes#day:2026-03-13#room:Hall 113#track:care
IDF Europe Symposium: CGM in People with Obesity, Intermediate Hyperglycemia or Type 2 Diabetes#day:2026-03-13#room:Hall 113#track:care
IDF Europe Symposium: Closing Remarks on CGM, Personalization and the Golden Age of Diabetes Care#day:2026-03-13#room:Hall 113#track:care
AN INTERNATIONAL CONSENSUS ON THE DETECTION AND MONITORING OF EARLY-STAGE TYPE 1 DIABETES: A ROADMAP TO EUROPEAN IMPLEMENTATION#day:2026-03-13#room:Hall 113#track:care
CLOSING REMARKS#day:2026-03-13#room:Hall 113#track:care
第一型糖尿病早期篩檢與監測的國際共識:邁向預防的藍圖#day:2026-03-13#room:Hall 113#track:care
血糖異常與糖尿病患者的連續血糖監測(CGM)與心血管風險管理#day:2026-03-13#room:Hall 113#track:care
Sufyan Hussain|AN INTERNATIONAL CONSENSUS ON THE DETECTION AND MONITORING OF EARLY-STAGE TYPE 1 DIABETES: A ROADMAP TO EUROPEAN IMPLEMENTATION#day:2026-03-13#room:Hall 113#track:care
Marissa Hitchcock Town|#LANGUAGEMATTERS IN POPULATION SCREENING FOR STAGE 1 T1D#day:2026-03-13#room:Hall 113#track:care
Tsvetalina Tankova|CARDIOVASCULAR DISEASE PREVENTION FOR PEOPLE WITH DYSGLYCEMIA AND DIABETES#day:2026-03-13#room:Hall 113#track:care
Sanja Klobucar|THE USE OF CONTINUOUS GLUCOSE MONITORING IN PEOPLE LIVING WITH OBESITY, INTERMEDIATE HYPERGLYCEMIA OR TYPE 2 DIABETES#day:2026-03-13#room:Hall 113#track:care- Tadej Battelino|CLOSING REMARKS#day:2026-03-13#room:Hall 113#track:care
Parallel Scientific 20: Beyond the Basics — Elevating Diabetes Nursing
幫助兒科患者選擇最適合的糖尿病科技與圍手術期的應用挑戰#day:2026-03-13#room:Hall 115#track:care
為糖尿病孩童選擇最適合的糖尿病科技:量身定制的個人化方法 (How to Help Our Children With Diabetes Choose The Best Diabetes Technology For Them: A Tailored and Personalized Method)#day:2026-03-13#room:Hall 115#track:care
飲食順序對於各類族群(第一型、第二型糖尿病與糖尿病前期)的益處 (Benefits of Meal Sequencing)#day:2026-03-13#room:Hall 115#track:care
Devorah Shapiro|HOW TO HELP OUR CHILDREN WITH DIABETES CHOOSE THE BEST DIABETES TECHNOLOGY FOR THEM? A TAILORED AND PERSONALIZED METHOD#day:2026-03-13#room:Hall 115#track:care
Shevy Serhofer|TO WEAR OR NOT TO WEAR: SUPPORTING DIABETES TECHNOLOGY IN THE OPERATING ROOM#day:2026-03-13#room:Hall 115#track:care
Jane J. Seley|“TO WEAR OR NOT TO WEAR” INTEGRATING WEARABLE TECHNOLOGY INTO ADULT DIABETES CARE#day:2026-03-13#room:Hall 115#track:care
Parallel Scientific 21: Equity and Innovation in Diabetes — Challenges, Disparities, and Breakthroughs
挑戰醫療產業現狀:縮小科技獲取的落差#day:2026-03-13#room:Hall 116#track:care
知覺歧視在糖尿病健康差異中的角色:未受充分代表族群的經驗#day:2026-03-13#room:Hall 116#track:care
RANDOMIZED TRIAL OF AN ADAPTIVE AI-BASED VR SPORTS SYSTEM FOR ADOLESCENTS AT RISK OF TYPE 2 DIABETES#day:2026-03-13#room:Hall 116#track:care
Partha Kar|CHALLENGING INDUSTRY OR WIDENING GAPS IN ACCESS TO TECHNOLOGY#day:2026-03-13#room:Hall 116#track:care
Ananta Addala|THE ROLE OF PERCEIVED DISCRIMINATION IN DIABETES DISPARITIES: EXPERIENCE OF UNDERREPRESENTED INDIVIDUALS#day:2026-03-13#room:Hall 116#track:care
Banshi Saboo|SHOWCASING AREA-SIDE IMPROVEMENT IN TYPE 1 DIABETES ACROSS INDIA#day:2026-03-13#room:Hall 116#track:care
Wu Qian|RANDOMIZED TRIAL OF AN ADAPTIVE AI-BASED VR SPORTS SYSTEM FOR ADOLESCENTS AT RISK OF TYPE 2 DIABETES#day:2026-03-13#room:Hall 116#track:care- Q&A|Q&A#day:2026-03-13#room:Hall 116#track:care






















